Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology
company developing novel, multifunctional biotherapeutics, today
announced the appointment of Mr. Carlos E. Campoy to its board of
directors effective as of June 30, 2023. Mr. Campoy brings
extensive strategic and financial leadership experience in the
pharmaceutical and biotechnology sectors to the Zymeworks board of
directors. He was also appointed as a member of the audit committee
and the nominating and corporate governance committee of the board
of directors.
Mr. Campoy succeeds Dr. Natalie Sacks, who will step down
effective as of June 30 after a successful 6-year tenure as board
director of Zymeworks.
“Carlos’ extensive global experience in financial leadership
positions in the pharmaceutical and biotechnology industries over
twenty-five years makes him a valuable addition to the Zymeworks
board of directors. He is a skillful, thoughtful, and
performance-driven financial executive with a successful track
record in leading culturally diverse organizations through complex
transformational changes in the U.S. and internationally, and I
look forward to working with him on the board of directors,” said
Kenneth Galbraith, Chair and Chief Executive Officer of
Zymeworks.
“The entire Zymeworks’ board of directors and employees are
sincerely grateful to Dr. Sacks for her dedicated service to
Zymeworks. She has been a significant contributor to Zymeworks’
efforts to advance multiple candidates in our development pipeline,
as well as the establishment of valuable industry partnerships. We
are grateful to have worked with her and extend our sincerest
wishes for her continued success.”
“I’m very pleased to have the opportunity to join the board of
directors at Zymeworks at such an exciting time for the company,”
said Mr. Campoy. “I look forward to leveraging my financial and
operating experience in the pharmaceutical and biotechnology
industries to support Zymeworks’ future efforts in clinical
development and commercialization of novel medicines for patients
with difficult-to-treat cancers. Additionally, I am also committed
to supporting a culture of diversity and individual
fulfillment.”
Mr. Campoy began his life sciences industry career at Eli Lilly
and Company in 1996, serving in a variety of senior financial
leadership roles in the U.S., Japan, Latin America and Europe over
an 18-year span. As the Chief Financial Officer at Alder
Biopharmaceuticals in Seattle, Washington, he led successful
capital markets transactions to fund commercialization readiness
for eptinezumab and played a key role in the eventual acquisition
of Alder Biopharmaceuticals by Lundbeck in 2019 in a cash
transaction in excess of $2 billion. He also previously held
financial leadership positions at Allergan plc and, most recently,
was the Chief Financial Officer at CytomX Therapeutics. He received
an M.B.A. in Finance and Decision Information Systems from Indiana
University and a Bachelor of Science degree in Management from
Faculdade C.C. Administracao de Tupa (FACCAT) in Brazil.
Egon Zehnder, a global leadership advisory firm, was actively
engaged with Zymeworks in an advisory capacity and assisted in the
recruitment of Mr. Campoy to the Zymeworks’ board of directors.
About Zymeworks Inc.
Zymeworks Inc. (Nasdaq: ZYME) is a global biotechnology company
committed to the discovery, development, and commercialization of
novel, multifunctional biotherapeutics. Zymeworks' mission is to
make a meaningful difference for people impacted by
difficult-to-treat cancers and other serious diseases. Zymeworks'
complementary therapeutic platforms and fully integrated drug
development engine provide the flexibility and compatibility to
precisely engineer and develop highly differentiated antibody-based
therapeutic candidates. Zymeworks engineered and developed
zanidatamab, a HER2-targeted bispecific antibody using Zymeworks'
proprietary Azymetric™ technology. Zymeworks has entered into
separate agreements with BeiGene, Ltd. (BeiGene) and Jazz
Pharmaceuticals Ireland Limited (Jazz), granting each of
BeiGene and Jazz with exclusive rights to develop and commercialize
zanidatamab in different territories. Zanidatamab is currently
being evaluated in global Phase 1, Phase 2, and Phase 3 clinical
trials, including certain ongoing pivotal clinical trials as a
treatment for patients with HER2-expressing cancers. Zymeworks'
next clinical candidate, zanidatamab zovodotin (ZW49), is a
HER2-targeted bispecific antibody-drug conjugate (ADC) developed
using Zymeworks' proprietary Azymetric™ and ZymeLink™ Auristatin
technologies. Zanidatamab zovodotin is currently being evaluated in
a Phase 1 clinical trial for patients with a variety of
HER2-expressing, HER2-amplified or HER2-mutant cancers. Zymeworks
is also advancing a deep pipeline of product candidates based on
its experience and capabilities in both ADC and multispecific
antibodies (MSAT). In addition to Zymeworks' wholly owned pipeline,
its therapeutic platforms have been further leveraged through
strategic partnerships with global biopharmaceutical companies. For
information about Zymeworks, visit www.zymeworks.com and
follow @ZymeworksInc on Twitter.
Cautionary Note Regarding Forward-Looking
Statements
This press release includes “forward-looking statements” or
information within the meaning of the applicable securities
legislation, including Section 27A of the Securities Act of 1933,
as amended, and Section 21E of the Securities Exchange Act of 1934,
as amended. Forward-looking statements in this press release
include, but are not limited to, statements that relate to
potential therapeutic effects and commercial potential of
zanidatamab and Zymeworks' other product candidates; Zymeworks’
clinical development of its product candidates and enrollment in
its clinical trials; the ability to advance product candidates into
later stages of development; and other information that is not
historical information. When used herein, words such as “plan”,
“believe”, “expect”, “may”, “continue”, “anticipate”, “potential”,
“will”, “progress”, and similar expressions are intended to
identify forward-looking statements. In addition, any statements or
information that refer to expectations, beliefs, plans,
projections, objectives, performance or other characterizations of
future events or circumstances, including any underlying
assumptions, are forward-looking. All forward-looking statements
are based upon Zymeworks’ current expectations and various
assumptions. Zymeworks believes there is a reasonable basis for its
expectations and beliefs, but they are inherently uncertain.
Zymeworks may not realize its expectations, and its beliefs may not
prove correct. Actual results could differ materially from those
described or implied by such forward-looking statements as a result
of various factors, including, without limitation: clinical trials
may not demonstrate safety and efficacy of any of Zymeworks’ or its
collaborators’ product candidates; any of Zymeworks’ or its
partners’ product candidates may fail in development, may not
receive required regulatory approvals, or may be delayed to a point
where they are not commercially viable; regulatory agencies may
impose additional requirements or delay the initiation of clinical
trials; the impact of new or changing laws and regulations; market
conditions; and the factors described under “Risk Factors” in
Zymeworks’ quarterly and annual reports filed with the Securities
and Exchange Commission, including its Quarterly Report on Form
10-Q for its quarter ended March 31, 2023 (a copy of which may be
obtained at www.sec.gov and www.sedar.com).
Although Zymeworks believes that such forward-looking statements
are reasonable, there can be no assurance they will prove to be
correct. Investors should not place undue reliance on
forward-looking statements. The above assumptions, risks and
uncertainties are not exhaustive. Forward-looking statements are
made as of the date hereof and, except as may be required by law,
Zymeworks undertakes no obligation to update, republish, or revise
any forward-looking statements to reflect new information, future
events or circumstances, or to reflect the occurrences of
unanticipated events.
Contacts:
Investor and Media Inquiries:
Diana PapoveDirector, Corporate Communications(604)
678-1388ir@zymeworks.com media@zymeworks.com
Zymeworks (NASDAQ:ZYME)
過去 株価チャート
から 4 2024 まで 5 2024
Zymeworks (NASDAQ:ZYME)
過去 株価チャート
から 5 2023 まで 5 2024